Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization
Status:
Active, not recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The proposed study seeks to evaluate the scar reduction capacity of BTA on excision/biopsy
wounds compared to the control (normal saline) in a double-blinded randomized control trial.
It will expand upon previous studies that have already demonstrated the safety and good
tolerance profile of BTA. We will be conducting a split-scar study/study involving two biopsy
sites in a singular patient, allowing them to serve as their own control. In keeping with the
results from previously conducted studies, we hypothesize that the wounds treated with BTA
will have significantly less evidence of scar formation than those sites treated with normal
saline.